Summary • Immunic, Inc. (IMUX) rises 5.8% in pre-market trading ahead of a healthcare conference. • CEO Daniel Vitt to participate in a chat at the Evercore ISI Healthcare Conference o 4, 2025. • Year ...

Fintel reports that on November 14, 2025, HC Wainwright & Co. maintained coverage of Immunic (NasdaqGS:IMUX) with a Buy recommendation. Analyst Price Forecast Suggests 718.72% Upside As of November 9, ...

Fintel reports that on September 25, 2025, D. Boral Capital maintained coverage of Immunic (NasdaqGS:IMUX) with a Buy recommendation. Analyst Price Forecast Suggests 763.73% Upside As of September 13, ...

Vidofludimus calcium achieved strong Phase 2 results in progressive multiple sclerosis, showing up to a 34.4% reduction in 24-week confirmed disability worsening events in the primary progressive MS ...

Immunic (NASDAQ:IMUX – Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.24) per ...

Several research analysts recently weighed in on the stock. D. Boral Capital restated a “buy” rating and issued a $17.00 price objective on shares of Immunic in a research report on Thursday, February ...

In a challenging market environment, Immunic, Inc. (NASDAQ: IMUX) stock has reached a 52-week low, dipping to $0.97. According to InvestingPro data, the company maintains a strong liquidity position ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

R&D Expenses: $18.3 million for Q2 2024, down from $21.2 million in Q2 2023. G&A Expenses: $4.5 million for Q2 2024, up from $3.8 million in Q2 2023. Net Loss: $21.4 million for Q2 2024, or $0.21 per ...